Protocol Ledger

NCT06481085 · Phase II · COMPLETED

To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

Interventional Phase II clinical trial protocol NCT06481085 sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-27 Enrollment: 324 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06481085
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)324 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06481085
Protocol FieldVerified Registry Value
NCT IdentifierNCT06481085
Consolidated Lead SponsorHangzhou Zhongmei Huadong Pharmaceutical Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment324 participants (ACTUAL)
Registered Start Date2024-06-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06481085
Hospital Research SiteLocationSite Profile
The Second Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
Zhejiang Provincial People's HospitalHangzhou, ChinaOpen Hospital Dossier ->
The Second Affiliated Hospital of Anhui Medical UniversityHefei, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI